Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022

Autor: Namrata Prasad, Gordana Derado, Srinivas Acharya Nanduri, Hannah E. Reses, Heather Dubendris, Emily Wong, Minn Minn Soe, Qunna Li, Philip Dollard, Suparna Bagchi, Jonathan Edwards, Nong Shang, Dan Budnitz, Jeneita Bell, Jennifer R. Verani, Andrea Benin, Ruth Link-Gelles, John Jernigan, Tamara Pilishvili
Rok vydání: 2022
Předmět:
Zdroj: MMWR. Morbidity and mortality weekly report. 71(18)
ISSN: 1545-861X
Popis: Nursing home residents have experienced disproportionally high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1). Following reported declines in vaccine-induced immunity after primary series vaccination, defined as receipt of 2 primary doses of an mRNA vaccine (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) or 1 primary dose of Ad26.COV2 (JohnsonJohnson [Janssen]) vaccine (2), CDC recommended that all persons aged ≥12 years receive a COVID-19 booster vaccine dose.* Moderately to severely immunocompromised persons, a group that includes many nursing home residents, are also recommended to receive an additional primary COVID-19 vaccine dose.
Databáze: OpenAIRE